Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revised US Approach For Parenteral Drug Leachables Could Prevent Regulatory Missteps

Executive Summary

Broad agreement across US FDA on modified PQRI recommendations could reduce approval delays over risk of chemicals leaching into parenteral drugs.

You may also be interested in...


...manufacturers are exploring how quality-by-design concepts apply in the context of the complexities of the drug/device interface. The challenges surrounding the control of leachables and extractables and how the supplier relationships fit into the QbD effort are particular focal points of attention. New industry guidances on L&Es and supplier GMPs from the Product Quality Research Institute and the International Pharmaceutical Aerosol Consortium on Regulation and Science, respectively, are helping move the dialogue forward and tighten the communication linkages. [Summary reports from three breakout sessions at a recent IPAC-RS conference – on supplier quality control, parametric tolerance interval testing and application of ISO standards – are provided.]

Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections

US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up. 

Children’s Hospital Resumes FDA-Funded Study Of PEG 3350 Pediatric Risks

New FDA assays may show whether polyethylene glycol laxative leaves toxic analytes and metabolites in children with chronic constipation – with potential implications for numerous other products.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts